Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of Direclidine Capsule vs Solution
NCT04935320Phase 1Completed
- Sponsor
- Nxera Pharma
- Start
- Jul 2021
- Primary completion
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of direclidine in schizophrenia (3 arms), sponsored by Nxera Pharma. Primary endpoints: Maximum Plasma Concentration and Area Under the Plasma Concentration-Time Curve. Started Jul 2021; status: completed.
02
Drugs
direclidine
03
Conditions
schizophrenia
Beyond the preview
Go deeper on NCT04935320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04935320.